Diagonal Bio AB

DIABIO

SE0015961826

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:31 2024-04-23 am EDT			5-day change	1st Jan Change
0.0899 ^SEK	-2.28%		-15.82%	-74.53%

Apr. 05	Diagonal Bio AB Announces the Extension of Its Partnership with Horsholm Veterinary Clinic	CI
Apr. 05	Diagonal Bio AB Announces Successful Pilot Study Results	CI

Diagonal Bio AB has completed an IPO in the amount of SEK 40.053962 million.

July 13, 2021 at 12:00 am EDT

Diagonal Bio AB (publ) has completed an IPO in the amount of SEK 40.053962 million. Security Name: Shares Security Type: Common Stock Securities Offered: 3,814,663 PriceRange: SEK 10.5

Latest news about Diagonal Bio AB

Diagonal Bio AB Announces the Extension of Its Partnership with Horsholm Veterinary Clinic	Apr. 05	CI
Diagonal Bio AB Announces Successful Pilot Study Results	Apr. 05	CI
Diagonal Bio Makes Interim CEO Permanent	Feb. 29	MT
Diagonal Bio Appoints Karin Wehlin as New CEO	Feb. 28	CI
Diagonal Bio AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Diagonal Bio Signs Product Distribution Deal With Techtum Lab	Feb. 16	MT
Diagonal Bio AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Diagonal Bio AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Diagonal Bio AB announced that it expects to receive SEK 1.8 million in funding	23-08-21	CI
Diagonal Bio AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Diagonal Bio AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-23	CI
Diagonal Bio AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Diagonal Bio AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-23	CI
Certain Shares of Diagonal Bio AB are subject to a Lock-Up Agreement Ending on 16-JUL-2022.	22-07-15	CI
Diagonal Bio AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Diagonal Bio AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-23	CI
Diagonal Bio AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-23	CI
Diagonal Bio AB has completed an IPO in the amount of SEK 40.053962 million.	21-07-13	CI
Diagonal Bio AB has filed an IPO in the amount of SEK 40.053962 million.	21-06-09	CI

Diagonal Bio AB is a Sweden-based medical research company. The Company is developing a diagnostic platform (Panviral) for detection of any kind of pathogen. Panviral's technology is based on rapid isothermal amplification of a pathogen's genome. Multiple tests can be run in parallel, thereby increasing the sample throughput.

Sector

Biotechnology & Medical Research

Calendar

2024-05-30 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DIAGONAL BIO AB	-74.53%	337K
IQVIA HOLDINGS INC.	+3.13%	42.11B
LONZA GROUP AG	+48.83%	40.08B
MODERNA, INC.	+8.49%	40B
CELLTRION, INC.	-10.82%	26.87B
ICON PUBLIC LIMITED COMPANY	+8.26%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	11.94B
MEDPACE HOLDINGS, INC.	+32.83%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.01B